CAL-101 (Idelalisib, GS-1101)

CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

Price Stock Quantity  
USD 156 In stock
USD 120 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

CAL-101 (Idelalisib, GS-1101) Chemical Structure

CAL-101 (Idelalisib, GS-1101) Chemical Structure
Molecular Weight: 415.42

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

CAL-101 (Idelalisib, GS-1101) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

  • Pan PI3K Inhibitor

    LY294002 Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.

  • Most Potent PI3K Inhibitor

    Duvelisib (IPI-145, INK1197) PI3K δ, IC50=1 nM.

  • PI3K Inhibitor in Clinical Trial

    Hexestrol Phase II for Advanced Breast Cancer.

  • Newest PI3K Inhibitor

    GSK2636771 Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Targets p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110α [1]
(Cell-free assay)

 View  More

IC50 2.5 nM 89 nM 565 nM 820 nM
In vitro CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. [1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. [2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). [3]
In vivo

Protocol(Only for Reference)

Kinase Assay: [2]

PI3K assay PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.

Cell Assay: [2]

Cell lines CLL B cells or healthy volunteer T cells or NK cells
Concentrations 0.01-100 μM
Incubation Time 48 hours
Method MTT assays are performed to determine cytotoxicity. 1 × 105 cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm2 flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Lannutti BJ, et al. Blood, 2011, 117(2), 591-594.

[2] Herman SE, et al. Blood, 2010, 116(12), 2078-2088.

view more

Clinical Trial Information( data from, updated on 2015-11-14)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02536300 Not yet recruiting Follicular Lymphoma|Small Lymphocytic Lymphoma Gilead Sciences November 2015 Phase 3
NCT02590588 Not yet recruiting Amyloidosis John Mark Sloan|Gilead Sciences|Boston Medical Center October 2015 Phase 2
NCT02538614 Not yet recruiting Chronic Lymphocytic Leukemia (CLL) Gilead Sciences|Boehringer Ingelheim October 2015 Phase 1|Phase 2
NCT02439138 Recruiting Waldenstroms Macroglobulinemia Dana-Farber Cancer Institute|Gilead Sciences October 2015 Phase 2
NCT02258529 Recruiting Follicular Lymphoma|Small Lymphocytic Lymphoma Gilead Sciences September 2015 Phase 2

view more

Chemical Information

Download CAL-101 (Idelalisib, GS-1101) SDF
Molecular Weight (MW) 415.42


CAS No. 870281-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 83 mg/mL warmed (199.79 mM)
Ethanol 23 mg/mL (55.36 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG 400 (dissolve first)/0.5% Tween 80/5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one

Customer Product Validation (4)

Click to enlarge
Source J Immunol, 2014, 192(5): 2063-70 . CAL-101 (Idelalisib, GS-1101) purchased from Selleck
Method Invasion Assay
Cell Lines Fibroblast-like synoviocytes
Concentrations 5 µM
Incubation Time 24 h
Results FLS were pretreated with INK007 (PI3Kδ), CAL-101 (PI3Kδ), IPI-145 (PI3Kδ/γ), or GDC-0941 (panPI3K) and cultured in Matrigel invasion chambers for 16 h. The PI3Kδ inhibitors decreased invasion by 50–60% (p < 0.04) compared with vehicle-treated control. As 眏Ỵ眐㠞眎膉癠 皐﷘ř᐀ŔřĀ 㺣癞帉癞

Click to enlarge
Source Cell Death Differ 2014 21(10), 1535-45. CAL-101 (Idelalisib, GS-1101) purchased from Selleck
Method Western blot
Cell Lines 293T cells
Concentrations 10 uM
Incubation Time 4 h
Results It treated PC-3 cells with AKT kinase inhibitor (CAL-101) to promote Par-4 translocation to the nucleus. As shown in figure , CAL-101 treatment promoted Par-4 nuclear translocation and diminished the interaction between Par-4 and Fbxo45 in the cytoplasm.

Click to enlarge
Source Acta Pharmacol Sin 2013 34(9),1201-7. CAL-101 (Idelalisib, GS-1101) purchased from Selleck
Method Western blot
Cell Lines Rh30-Myr-p110s cells
Concentrations 0-6.6 uM
Incubation Time 1 h
Results CAL-101 significantly inhibited the phosphorylation of Akt in Rh30-Myr-p110α cells at the concentration of 2.2 umol/L, but was required to inhibit Akt phosphorylation to the same extent in Rh30-Myr-p110γ cells.

Click to enlarge
Source Dr. Zhang of Tianjin Medical University. CAL-101 (Idelalisib, GS-1101) purchased from Selleck
Method Western blot
Cell Lines A549 cells
Concentrations 0-1 μM
Incubation Time 3 h
Results Reduction of AKT phosphorylation in A549 cells treated with CAL-101 was observed.

Product Use Citation (25)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy CAL-101 (Idelalisib, GS-1101) | CAL-101 (Idelalisib, GS-1101) supplier | purchase CAL-101 (Idelalisib, GS-1101) | CAL-101 (Idelalisib, GS-1101) cost | CAL-101 (Idelalisib, GS-1101) manufacturer | order CAL-101 (Idelalisib, GS-1101) | CAL-101 (Idelalisib, GS-1101) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us